Literature DB >> 27354268

Dissection of the Major Hematopoietic Quantitative Trait Locus in Chromosome 6q23.3 Identifies miR-3662 as a Player in Hematopoiesis and Acute Myeloid Leukemia.

Sophia E Maharry1, Christopher J Walker1, Sandya Liyanarachchi1, Sujay Mehta1, Mitra Patel1, Maryam A Bainazar1, Xiaomeng Huang1, Malori A Lankenau1, Kevin W Hoag1, Parvathi Ranganathan1, Ramiro Garzon1, James S Blachly1, Denis C Guttridge1, Clara D Bloomfield1, Albert de la Chapelle1, Ann-Kathrin Eisfeld2.   

Abstract

UNLABELLED: Chromosomal aberrations and multiple genome-wide association studies (GWAS) have established a major hematopoietic quantitative trait locus in chromosome 6q23.3. The locus comprises an active enhancer region, in which some of the associated SNPs alter transcription factor binding. We now identify miR-3662 as a new functional driver contributing to the associated phenotypes. The GWAS SNPs are strongly associated with higher miR-3662 expression. Genome editing of rs66650371, a three-base-pair deletion, suggests a functional link between the SNP genotype and the abundance of miR-3662. Increasing miR-3662's abundance increases colony formation in hematopoietic progenitor cells, particularly the erythroid lineage. In contrast, miR-3662 is not expressed in acute myeloid leukemia cells, and its overexpression has potent antileukemic effects in vitro and in vivo Mechanistically, miR-3662 directly targets NF-κB-mediated transcription. Thus, miR-3662 is a new player of the hematopoietic 6q23.3 locus. SIGNIFICANCE: The characterization of miR-3662 has identified a new actor in the prominent hematopoietic quantitative trait locus in chromosome 6q23.3. The mechanistic insights into miR-3662's function may reveal novel or only partially known pathways for normal and malignant hematopoietic cell proliferation. Cancer Discov; 6(9); 1036-51. ©2016 AACR.This article is highlighted in the In This Issue feature, p. 932. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27354268      PMCID: PMC5168803          DOI: 10.1158/2159-8290.CD-16-0023

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  43 in total

Review 1.  NF-kappaB and the regulation of hematopoiesis.

Authors:  V Bottero; S Withoff; I M Verma
Journal:  Cell Death Differ       Date:  2006-05       Impact factor: 15.828

2.  The HBS1L-MYB intergenic interval associated with elevated HbF levels shows characteristics of a distal regulatory region in erythroid cells.

Authors:  Karin Wahlberg; Jie Jiang; Helen Rooks; Kiran Jawaid; Fumihiko Matsuda; Masao Yamaguchi; Mark Lathrop; Swee Lay Thein; Steve Best
Journal:  Blood       Date:  2009-06-15       Impact factor: 22.113

3.  Sequence variants in three loci influence monocyte counts and erythrocyte volume.

Authors:  Manuel A R Ferreira; Jouke-Jan Hottenga; Nicole M Warrington; Sarah E Medland; Gonneke Willemsen; Robert W Lawrence; Scott Gordon; Eco J C de Geus; Anjali K Henders; Johannes H Smit; Megan J Campbell; Leanne Wallace; David M Evans; Margaret J Wright; Dale R Nyholt; Alan L James; John P Beilby; Brenda W Penninx; Lyle J Palmer; Ian H Frazer; Grant W Montgomery; Nicholas G Martin; Dorret I Boomsma
Journal:  Am J Hum Genet       Date:  2009-10-22       Impact factor: 11.025

4.  Dynamic long-range chromatin interactions control Myb proto-oncogene transcription during erythroid development.

Authors:  Ralph Stadhouders; Supat Thongjuea; Charlotte Andrieu-Soler; Robert-Jan Palstra; Jan Christian Bryne; Anita van den Heuvel; Mary Stevens; Ernie de Boer; Christel Kockx; Antoine van der Sloot; Mirjam van den Hout; Wilfred van Ijcken; Dirk Eick; Boris Lenhard; Frank Grosveld; Eric Soler
Journal:  EMBO J       Date:  2011-12-13       Impact factor: 11.598

5.  Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.

Authors:  Parvathi Ranganathan; Xueyan Yu; Caroline Na; Ramasamy Santhanam; Sharon Shacham; Michael Kauffman; Alison Walker; Rebecca Klisovic; William Blum; Michael Caligiuri; Carlo M Croce; Guido Marcucci; Ramiro Garzon
Journal:  Blood       Date:  2012-06-07       Impact factor: 22.113

6.  The C-MYB locus is involved in chromosomal translocation and genomic duplications in human T-cell acute leukemia (T-ALL), the translocation defining a new T-ALL subtype in very young children.

Authors:  Emmanuelle Clappier; Wendy Cuccuini; Anna Kalota; Antoine Crinquette; Jean-Michel Cayuela; Willem A Dik; Anton W Langerak; Bertrand Montpellier; Bertrand Nadel; Pierre Walrafen; Olivier Delattre; Alain Aurias; Thierry Leblanc; Hervé Dombret; Alan M Gewirtz; André Baruchel; Francois Sigaux; Jean Soulier
Journal:  Blood       Date:  2007-04-23       Impact factor: 22.113

7.  Dominant interfering alleles define a role for c-Myb in T-cell development.

Authors:  P Badiani; P Corbella; D Kioussis; J Marvel; K Weston
Journal:  Genes Dev       Date:  1994-04-01       Impact factor: 11.361

8.  Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1976-08       Impact factor: 6.998

Review 9.  Differentiation therapy of acute myeloid leukemia: past, present and future.

Authors:  Kevin Petrie; Arthur Zelent; Samuel Waxman
Journal:  Curr Opin Hematol       Date:  2009-03       Impact factor: 3.284

10.  HBS1L-MYB intergenic variants modulate fetal hemoglobin via long-range MYB enhancers.

Authors:  Ralph Stadhouders; Suleyman Aktuna; Supat Thongjuea; Ali Aghajanirefah; Farzin Pourfarzad; Wilfred van Ijcken; Boris Lenhard; Helen Rooks; Steve Best; Stephan Menzel; Frank Grosveld; Swee Lay Thein; Eric Soler
Journal:  J Clin Invest       Date:  2014-03-10       Impact factor: 14.808

View more
  6 in total

1.  Precancer Atlas to Drive Precision Prevention Trials.

Authors:  Avrum Spira; Matthew B Yurgelun; Ludmil Alexandrov; Anjana Rao; Rafael Bejar; Kornelia Polyak; Marios Giannakis; Ali Shilatifard; Olivera J Finn; Madhav Dhodapkar; Neil E Kay; Esteban Braggio; Eduardo Vilar; Sarah A Mazzilli; Timothy R Rebbeck; Judy E Garber; Victor E Velculescu; Mary L Disis; Douglas C Wallace; Scott M Lippman
Journal:  Cancer Res       Date:  2017-04-01       Impact factor: 13.312

2.  GWAS and PheWAS of red blood cell components in a Northern Nevadan cohort.

Authors:  Robert W Read; Karen A Schlauch; Gai Elhanan; William J Metcalf; Anthony D Slonim; Ramsey Aweti; Robert Borkowski; Joseph J Grzymski
Journal:  PLoS One       Date:  2019-06-13       Impact factor: 3.240

3.  Validation of prostate cancer risk variants rs10993994 and rs7098889 by CRISPR/Cas9 mediated genome editing.

Authors:  Xing Wang; James E Hayes; Xing Xu; Xiaoni Gao; Dipti Mehta; Hans G Lilja; Robert J Klein
Journal:  Gene       Date:  2020-10-26       Impact factor: 3.688

4.  MiR-3662 suppresses hepatocellular carcinoma growth through inhibition of HIF-1α-mediated Warburg effect.

Authors:  Zhiqiang Chen; Xueliang Zuo; Yao Zhang; Guoyong Han; Long Zhang; Jindao Wu; Xuehao Wang
Journal:  Cell Death Dis       Date:  2018-05-01       Impact factor: 8.469

5.  Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA.

Authors:  Christopher J Walker; Christopher C Oakes; Luke K Genutis; Brian Giacopelli; Sandya Liyanarachchi; Deedra Nicolet; Ann-Kathrin Eisfeld; Markus Scholz; Pamela Brock; Jessica Kohlschmidt; Krzysztof Mrózek; Marius Bill; Andrew J Carroll; Jonathan E Kolitz; Bayard L Powell; Eunice S Wang; Dietger W Niederwieser; Richard M Stone; John C Byrd; Sebastian Schwind; Albert de la Chapelle; Clara D Bloomfield
Journal:  Leukemia       Date:  2018-10-05       Impact factor: 11.528

6.  CRISPR interference and activation of the microRNA-3662-HBP1 axis control progression of triple-negative breast cancer.

Authors:  Baozhu Yi; Shuaibin Wang; Xinran Wang; Zhichao Liu; Chao Zhang; Ming Li; Song Gao; Shi Wei; Sejong Bae; Erica Stringer-Reasor; Lizhong Wang; Runhua Liu
Journal:  Oncogene       Date:  2021-11-02       Impact factor: 9.867

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.